AstraZeneca Appoints New Head for China Business Amid Investigation

  • 📰 FT
  • ⏱ Reading Time:
  • 24 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 41%
  • Publisher: 51%

Business أخبار

Astrazeneca,China,Iskra Reic

AstraZeneca has appointed Iskra Reic as the new head of its China business following the detention of her predecessor Leon Wang. Wang is on 'extended leave' while under investigation in China, reportedly related to the illegal importation of cancer drug Imjudo. The investigation also includes charges of insurance fraud by other staff members related to the sales of lung cancer drug Tagrisso.

AstraZeneca has appointed a new head of its China business, after her predecessor Leon Wang was detained by authorities in the country as part of a crackdown on the healthcare sector. Iskra Reic will take over from Wang to lead the drugmaker’s business in the country and will be based at the company’s research and development centre in Shanghai, the company said on Wednesday. The UK-listed group added that Wang was on “extended leave” while under investigation in China.

He was a well-known figure in the industry in China, with deep knowledge and contacts. Reic, a Croatian national whose job title will be “executive vice-president, international”, has worked mainly in Europe and Russia. She has no previous experience in China. She has been at the company since 2001, most recently launching the company’s vaccines and immune therapies unit, after it developed a Covid-19 shot with the University of Oxford during the pandemic.

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 113. in AE
 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين